A stock in the biotechnology and drugs complex that's setting up for a near-term breakout trade is
(HEB - Get Report)
, which is engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. This stock has been on fire so far in 2012, with shares up around 380%.
This company has a major catalyst on the horizon, since it will meet with the FDA on Feb. 1, 2013, for the possible approval of its drug Ampligen, which treats chronic fatigue syndrome. This stock has already started to run-up ahead of that catalyst, but there could be plenty more upside where that came from.
If you take a look at the chart for Hemispherx BioPharma, you'll notice that this stock has been uptrending very strong for the last three months, with shares soaring from a low of 25 cents to its recent high of 96 cents. During that uptrend, shares of HEB have been consistently making higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by heavy upside volume, especially during the last month and a half. Shares of HEB are quickly moving within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in HEB if it can manage to take out some near-term overhead resistance levels at 95 cents to $1.01 a share with high volume. Look for a sustained move or close above those levels with volume that tracks in close to or above its three-month average action of 1.3 million shares. If that breakout triggers soon, then HEB will have a great chance of doubling and hitting $2 a share.
One can look to buy HEB off any weakness and anticipate that breakout and simply use a stop that sits right around some near-term support at 75 cents to 72 cents per share. One could also buy off strength once HEB clears 95 cents to $1.01 a share with volume, and then simply use a stop at around 90 cents to 88 cents per share.